For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Caladrius Biosciences been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Caladrius Biosciences is one of 756 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CLBS is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLBS's full-year earnings has moved 5.45% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CLBS has gained about 60.11% so far this year. At the same time, Medical stocks have gained an average of 6.46%. As we can see, Caladrius Biosciences is performing better than its sector in the calendar year.
Looking more specifically, CLBS belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have lost 1.62% this year, meaning that CLBS is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CLBS as it looks to continue its solid performance.
Image: Bigstock
Is Caladrius Biosciences (CLBS) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Caladrius Biosciences been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Caladrius Biosciences is one of 756 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CLBS is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLBS's full-year earnings has moved 5.45% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CLBS has gained about 60.11% so far this year. At the same time, Medical stocks have gained an average of 6.46%. As we can see, Caladrius Biosciences is performing better than its sector in the calendar year.
Looking more specifically, CLBS belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have lost 1.62% this year, meaning that CLBS is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CLBS as it looks to continue its solid performance.